NTRA

Natera Inc

279.32

Jul 02 • 04:00PM ET +3.05 (1.10%)

Healthcare Diagnostics & Research USA Large NASD

Peers: IQV LH ICLR DHR IDXX TMO A WAT MTD BIO

| Held by: VTI VB VBK VXF IBB IWP IWR IWF XBI FBT

Scroll to Statements

Index	-
Market Cap	40.00B
Enterprise Value	39.16B
Income	-226.31M
Sales	2.50B
Book/sh	12.43
Cash/sh	7.60
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	6140
IPO	Jul 02, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	16.00
P/B	22.47
P/C	36.77
P/FCF	382.77
EV/EBITDA	-
EV/Sales	15.66
Quick Ratio	2.83
Current Ratio	2.96
Debt/Eq	0.14
LT Debt/Eq	0.08
Option/Short	Yes / Yes

EPS (ttm)	-1.64
EPS next Y	-0.30
EPS next Q	-0.49
EPS this Y	-6.21%
EPS next Y	81.45%
EPS next 5Y	-
EPS past 3/5Y	35.09% 11.70%
Sales past 3/5Y	41.14% 42.61%
EPS Y/Y TTM	-11.94%
Sales Y/Y TTM	36.59%
EPS Q/Q	-21.06%
Sales Q/Q	38.82%
Earnings	May 07 AMC
EPS/Sales Surpr.	-10.66% 12.89%

Insider Own	4.42%
Insider Trans	-12.60%
Inst Own	93.90%
Inst Trans	1.70%
ROA	-10.41%
ROE	-15.02%
ROIC	-11.79%
Gross Margin	64.77%
Oper. Margin	-12.81%
Profit Margin	-9.05%
SMA20	17.31%
SMA50	28.11%
SMA200	32.60%
Trades

Shs Outstand	142.73M
Shs Float	136.88M
Short Float	3.15%
Short Ratio	2.75
Short Interest	4.32M
52W High	279.42 -0.04%
52W Low	131.81 111.91%
Volatility	4.25% 5.26%
ATR (14)	12.26
RSI (14)	78.00
Beta	1.51
Rel Volume	0.81
Avg Volume	1.57M
Volume	1,273,873

Perf Week	7.13%
Perf Month	31.30%
Perf Quarter	37.45%
Perf Half Y	21.45%
Perf YTD	21.93%
Perf Year	72.88%
Perf 3Y	474.02%
Perf 5Y	139.02%
Perf 10Y	2174.59%
Recom	1.42
Target Price	265.52
Prev Close	276.27
Price	279.32
Change	1.10%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-26-26	Resumed	Bernstein	Outperform	$310
Jun-12-26	Resumed	RBC Capital Mkts	Outperform	$275
Jun-02-26	Resumed	Wolfe Research	Outperform	$260
Apr-14-26	Initiated	William Blair	Outperform
Jan-07-26	Initiated	Citigroup	Buy	$300
Dec-02-25	Resumed	Morgan Stanley	Overweight	$265
Oct-27-25	Upgrade	BNP Paribas Exane	Underperform → Neutral	$172
Sep-22-25	Resumed	Wells Fargo	Equal Weight	$175
Mar-13-25	Initiated	RBC Capital Mkts	Outperform	$251
Jan-23-25	Initiated	Barclays	Overweight	$200
Jun-03-24	Resumed	Jefferies	Buy	$142
Apr-08-24	Resumed	Craig Hallum	Buy	$117
Feb-20-24	Downgrade	Raymond James	Strong Buy → Outperform	$68 → $85
Dec-29-23	Reiterated	BTIG Research	Buy	$75 → $85
Dec-14-23	Initiated	Guggenheim	Buy	$70
Dec-13-23	Initiated	Wolfe Research	Outperform	$70
Nov-13-23	Upgrade	Raymond James	Outperform → Strong Buy	$68
Sep-28-23	Initiated	Bernstein	Mkt Perform	$48
Jul-05-23	Resumed	JP Morgan	Overweight	$85
May-05-23	Initiated	UBS	Buy	$76

Show Previous Ratings

Jul-02-26 06:41PM	CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology (Exec Edge)
Jul-01-26 06:02PM	When Multi-Cancer Blood Screens Could Finally Take Off (Barrons.com)
05:41PM	SkylineDxs Merlin CP-GEP Granted FDA Breakthrough Device Designation (Exec Edge)
Jun-29-26 06:00AM	Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer (Business Wire)
Jun-25-26 07:00AM	Natera and Eledon Announce Strategic Partnership for Prospera Monitoring in Planned Phase 3 Kidney Transplant Trial (Business Wire)
05:00AM	Loading…
Jun-24-26 05:00AM	Signatera Receives Regulatory Approval in Japan for Colorectal Cancer (Business Wire) +10.74%
Jun-23-26 06:00AM	NCCN Recommends ctDNA-MRD Testing Using Signatera Technology in Landmark Bladder Cancer Guideline Update (Business Wire)
Jun-18-26 06:00AM	Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress (Business Wire)
Jun-05-26 10:40AM	Healthcare Stocks Can Benefit From AI, Too. But That Isn't the Reason to Buy Them. (Barrons.com)
09:36AM	Tesla upgraded, Lululemon downgraded: Wall Street's top analyst calls (The Fly)
Jun-04-26 08:00AM	Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer (Business Wire)
Jun-03-26 08:00AM	Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors (Business Wire)
May-29-26 06:00AM	Natera Announces Collaboration with Diakonos Oncology for Signatera in Refractory Melanoma (Business Wire)
May-28-26 06:00AM	Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer (Business Wire) +5.33%
May-26-26 06:00AM	Natera to Launch Enhanced Panorama NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology (Business Wire)
05:05PM	Loading…
May-21-26 05:05PM	Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology (Business Wire)
07:00AM	Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World (Business Wire)
May-20-26 04:51PM	Prenetics Starts Partnership with Jay Shetty as IM8 Global Ambassador & Shareholder (IPO-Edge.com)
07:00AM	EXPAND Trial of Nateras Fetal Focus Single-Gene NIPT Surpasses >2,000 Patients Enrolled (Business Wire)
May-15-26 05:18PM	Stanley Druckenmiller Exits State Street Financial Select Sector SPDR ETF, Impacting Portfolio ... (GuruFocus.com) -5.36%
12:45PM	Signatera CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC) (Business Wire)
12:01AM	Nateras Stronghold in Cancer Recurrence Tests Prompts Woods Ark to Expand Stake (The Daily Upside)
May-14-26 05:30AM	The Cancer Test That Wall Street Is Betting On (The Wall Street Journal)
May-07-26 05:22PM	Natera: Q1 Earnings Snapshot (Associated Press) -11.64%
04:05PM	Natera Reports First Quarter 2026 Financial Results (Business Wire)
May-06-26 09:31AM	Why The Dip In TEM Stock Is A Buying Window (Trefis)
Apr-30-26 08:00AM	Natera to Report its First Quarter Results on May 7, 2026 (Business Wire) +5.86%
Apr-23-26 12:33PM	SkylineDx Presents Gene Expression Profiling for Skin Cancer Metastases (Exec Edge)
Apr-22-26 09:00AM	Prospera Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT (Business Wire)
Apr-13-26 08:00AM	Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma (Business Wire)
06:00AM	Loading…
Apr-09-26 06:00AM	Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents (Business Wire)
Apr-07-26 06:00AM	20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera's Oncology Platform (Business Wire)
Mar-31-26 06:00AM	SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery (Business Wire) +7.04%
Mar-16-26 06:00AM	Two Publications Highlight Clinical Utility of Signatera in Anal and Rectal Cancers (Business Wire) +5.23%
Mar-12-26 08:00AM	Natera Announces Commercial Launch of Zenith Genomics for Rare Disease Diagnosis (Business Wire)
08:00AM	MyOme Debuts Zenith Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026 (PR Newswire)
Mar-09-26 12:41AM	3 Healthcare Stocks to Target This Week (StockStory)
Mar-04-26 07:10AM	Signatera Oncology Test Drives Natera's (NTRA) Growth (Insider Monkey)
Mar-03-26 03:35PM	Natera (NTRA) Stock Trades Up, Here Is Why (StockStory)
Feb-27-26 12:40PM	Why Natera (NTRA) Shares Are Falling Today (StockStory)
10:05AM	Signatera MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation (Business Wire)
08:30AM	Personalis, Inc. Q4 2025 Earnings Call Summary (Moby)
12:07AM	Natera Q4 Earnings Call Highlights (MarketBeat)
12:05AM	Natera Inc (NTRA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Outlook ... (GuruFocus.com)
Feb-26-26 11:53PM	Natera, Inc. (NTRA) Announces Results From the SINERGY Trial (Insider Monkey)
06:45PM	Natera (NTRA) Tops Q4 Earnings and Revenue Estimates (Zacks)
06:30PM	Natera (NTRA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
04:58PM	Natera: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Natera Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-24-26 10:28PM	Natera Earnings: What To Look For From NTRA (StockStory)
06:00AM	Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer (Business Wire)
Feb-23-26 09:15AM	Unveiling Natera (NTRA) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Feb-18-26 07:00PM	Allogene Therapeutics Teases April ALPHA3 Data as cema-cel Targets MRD+ LBCL in Remission (MarketBeat)
08:10AM	Charles River Laboratories (CRL) Q4 Earnings and Revenues Surpass Estimates (Zacks)
Feb-17-26 04:01PM	Stanley Druckenmiller's Strategic Moves: A Closer Look at State Street Financial Select Sector ... (GuruFocus.com)
09:00AM	Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026 (Business Wire)
Feb-12-26 07:27AM	Surgery Partners (SGRY) Moves 7.7% Higher: Will This Strength Last? (Zacks)
Feb-11-26 09:56AM	EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus (Zacks)
Feb-10-26 07:40AM	CVS Health (CVS) Tops Q4 Earnings and Revenue Estimates (Zacks)
Feb-06-26 06:00AM	Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes (Business Wire)
Feb-03-26 05:15PM	InnovAge Holding Corp. (INNV) Q2 Earnings and Revenues Surpass Estimates (Zacks) -9.69%
10:29AM	Natera Files Signatera CDx PMA With FDA for Bladder Cancer MRD Test (Zacks)
Feb-02-26 06:00AM	Natera Submits Signatera CDx PMA to FDA (Business Wire)
Jan-29-26 07:29AM	Natera, Inc. (NTRA) Reports Preliminary Q4 Revenue (Insider Monkey)
Jan-26-26 06:00AM	Prospera Featured in Landmark Interventional Study Advancing Lung Transplant Care (Business Wire)
Jan-25-26 11:38PM	2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds (StockStory)
Jan-23-26 10:53AM	Lack of Natera (NTRA) Exposure Weighs on Mid-Cap Fund Performance (Insider Monkey)
Jan-21-26 06:00AM	Natera Publishes Clinical Validation of Latitude Tissue-Free MRD Test in Colorectal Cancer (Business Wire)
Jan-20-26 06:00AM	Natera's Fetal Focus Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting (Business Wire)
Jan-13-26 10:45AM	NTRA & NVDA Partner to Improve AI Models for Precision Medicine (Zacks)
08:00AM	Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling (Business Wire)
Jan-12-26 10:00AM	Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA (Business Wire)
Jan-11-26 10:48PM	Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera Growth (Business Wire)
Jan-08-26 08:50AM	EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study (Zacks) -5.83%
Jan-07-26 02:11PM	Trade Tracker: Stephanie Link sells Eaton and buys more Zoetis, Natera (CNBC TV)
09:41AM	Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly)
08:04AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: Applied Digital, BigBear.ai, Block, Deckers Outdoors, GitLab, Hershey, McDonalds, Moderna, and More (24/7 Wall St.)
08:00AM	Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer (Business Wire)
Jan-05-26 07:25PM	Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI (Business Wire)
07:00AM	Natera Launches 21-Gene Fetal Focus Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP Technology (Business Wire)
Dec-31-25 11:56AM	Natera (NTRA) Announces Publication of Findings from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study (Insider Monkey)
Dec-30-25 02:16PM	Medical Stock Hovers Near Buy Point After 46% Gain (Investor's Business Daily)
Dec-26-25 03:40PM	Medical Stocks On The Move In Top Growth List As Health Sector Performance Brightens (Investor's Business Daily)
Dec-23-25 11:03PM	3 Reasons We're Fans of Natera (NTRA) (StockStory)
Dec-22-25 10:19PM	J.P. Morgan Lifts Natera, Inc. (NTRA) Target on Signatera Momentum (Insider Monkey)
08:00AM	Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-18-25 08:00AM	Natera Announces Publication of Signatera Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer (Business Wire)
Dec-12-25 08:00AM	Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer (Business Wire)
Dec-11-25 10:11AM	Crypto Market 2026 Predictions: Which Coins Will 10x and Which Will Crash? (24/7 Wall St.)
10:11AM	Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks (24/7 Wall St.)
Dec-10-25 07:57PM	Phase III PALLAS Study Shows Signatera MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer (Business Wire)
06:15AM	Natera acquires Foresight Diagnostics for up to $450M (MedTech Dive)
Dec-09-25 08:00AM	Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting (Business Wire)
Dec-08-25 04:46AM	Natera purchases Foresight Diagnostics (Medical Device Network)
Dec-05-25 07:00AM	Natera Acquires Foresight Diagnostics (Business Wire)
Dec-03-25 08:00AM	New Signatera Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting (Business Wire)
Dec-02-25 08:00AM	Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera at the San Antonio Breast Cancer Symposium (Business Wire)
Nov-30-25 03:14AM	30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks (Motley Fool)
Nov-24-25 07:00PM	Natera, GoodRx, and Bio-Techne Shares Are Soaring, What You Need To Know (StockStory)
12:38PM	This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks Hes Buying Now. (24/7 Wall St.)

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Co-Founder & Executive ChairmanDr. Matthew Rabinowitz Ph.D.

CEO & DirectorMr. Steven Leonard Chapman

President & Chief Business OfficerMr. John Fesko

Chief Financial OfficerMr. Michael B. Brophy M.B.A.

President of Clinical DiagnosticsMr. Solomon Moshkevich M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DANIEL RABINOWITZ	Officer	Jul 01 '26	Proposed Sale	271.45	16,800	4,560,360		Jul 01 04:15 PM
SOLOMON MOSHKEVICH	Officer	Jul 01 '26	Proposed Sale	272.90	3,000	818,710		Jul 01 04:13 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jun 24 '26	Sale	251.65	33,600	8,455,355	189,094	Jun 26 09:05 PM
ROSENMAN HERM	Director	Jun 24 '26	Sale	250.00	16,530	4,132,500	4,250	Jun 26 09:05 PM
DANIEL RABINOWITZ	Officer	Jun 24 '26	Proposed Sale	234.76	33,600	7,887,936		Jun 24 04:36 PM
HERMAN ROSENMAN	Director	Jun 24 '26	Proposed Sale	250.00	16,530	4,132,500		Jun 24 04:21 PM
Sheena Jonathan	CO-FOUNDER	Jun 17 '26	Sale	219.87	1,500	329,810	18,782	Jun 22 09:05 PM
Chapman Rowan E	Director	Jun 16 '26	Sale	216.78	2,964	642,536	3,124	Jun 17 09:05 PM
Sheena Jonathan	CO-FOUNDER	Jun 15 '26	Sale	211.14	3,150	665,087	249,352	Jun 17 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Jun 15 '26	Sale	214.91	50,000	10,745,662	2,277,843	Jun 16 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Jun 12 '26	Sale	214.03	50,000	10,701,645	2,327,843	Jun 16 09:35 PM
ROWAN EMMA CHAPMAN	Director	Jun 16 '26	Proposed Sale	216.78	2,964	642,536		Jun 16 04:02 PM
MATTHEW RABINOWITZ	Director	Jun 12 '26	Proposed Sale	219.23	100,000	21,923,000		Jun 12 04:42 PM
Marcus Gail Boxer	Director	Jun 05 '26	Option Exercise	22.83	11,000	251,130	17,183	Jun 09 09:05 PM
Marcus Gail Boxer	Director	Jun 05 '26	Sale	217.21	11,000	2,389,328	6,183	Jun 09 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jun 04 '26	Sale	221.03	41,124	9,089,776	108,743	Jun 05 09:05 PM
GAIL MARCUS	Director	Jun 05 '26	Proposed Sale	217.21	11,000	2,389,328		Jun 05 05:15 PM
STEVEN L CHAPMAN	Officer	Jun 04 '26	Proposed Sale	221.03	41,124	9,089,778		Jun 04 05:03 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jun 01 '26	Sale	218.43	3,000	655,295	137,643	Jun 03 09:05 PM
BOTHA ROELOF	Director	Jun 01 '26	Sale	220.31	78,000	17,184,092	1,076,198	Jun 03 04:40 PM
BV369 TRUST	Affiliate	Jun 01 '26	Proposed Sale	220.31	78,000	17,184,094		Jun 01 04:12 PM
SOLOMON MOSHKEVICH	Officer	Jun 01 '26	Proposed Sale	218.43	3,000	655,295		Jun 01 04:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	May 26 '26	Sale	202.84	1,652	335,091	140,643	May 28 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	May 26 '26	Sale	202.84	1,438	291,684	185,782	May 28 09:05 PM
Sheena Jonathan	CO-FOUNDER	May 08 '26	Sale	208.60	3,150	657,104	252,502	May 15 09:05 PM
Sheena Jonathan	CO-FOUNDER	May 13 '26	Sale	201.56	1,500	302,347	19,532	May 15 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	May 05 '26	Sale	213.77	6,986	1,493,363	2,376,402	May 06 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	May 04 '26	Sale	206.16	722	148,848	2,382,440	May 06 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	May 04 '26	Sale	210.49	482	101,456	57,496	May 05 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	May 01 '26	Sale	206.16	313	64,528	57,978	May 05 09:45 PM
Sheena Jonathan	CO-FOUNDER	May 01 '26	Sale	206.16	107	22,059	255,652	May 05 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	May 01 '26	Sale	203.69	3,405	693,560	142,295	May 05 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	May 01 '26	Sale	206.16	291	59,993	187,220	May 05 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	May 01 '26	Sale	206.16	902	185,956	149,867	May 05 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	May 01 '26	Sale	206.16	330	68,033	222,694	May 05 09:35 PM
MICHAEL BROPHY	Officer	May 04 '26	Proposed Sale	207.28	482	99,909		May 04 04:52 PM
SOLOMON MOSHKEVICH	Officer	May 01 '26	Proposed Sale	203.35	3,000	610,065		May 01 04:08 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 29 '26	Sale	193.74	3,070	594,789	58,291	Apr 29 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 27 '26	Sale	204.14	1,993	406,856	61,361	Apr 29 09:45 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Apr 27 '26	Sale	204.14	5,838	1,191,775	150,769	Apr 29 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Apr 27 '26	Sale	204.10	1,688	344,517	187,511	Apr 29 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Apr 27 '26	Sale	204.10	2,182	445,341	145,700	Apr 29 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Apr 27 '26	Sale	204.09	1,861	379,811	223,024	Apr 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Apr 29 '26	Sale	196.42	3,071	603,198	255,711	Apr 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Apr 27 '26	Sale	204.00	473	96,494	258,782	Apr 29 09:35 PM
MICHAEL BROPHY	Officer	Apr 29 '26	Proposed Sale	200.17	3,070	614,522		Apr 29 04:35 PM
Sheena Jonathan	CO-FOUNDER	Apr 17 '26	Sale	199.63	1,500	299,441	20,282	Apr 21 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Apr 06 '26	Option Exercise	9.59	58,292	559,020	2,410,772	Apr 08 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Apr 01 '26	Sale	203.31	8,400	1,707,814	224,885	Apr 03 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Apr 01 '26	Sale	202.30	3,000	606,899	147,882	Apr 03 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 31 '26	Option Exercise	9.59	41,708	399,980	2,352,480	Apr 01 09:05 PM
SOLOMON MOSHKEVICH	Officer	Apr 01 '26	Proposed Sale	202.30	3,000	606,899		Apr 01 04:05 PM
Sheena Jonathan	CO-FOUNDER	Mar 18 '26	Sale	198.17	3,070	608,370	259,255	Mar 20 09:05 PM
Sheena Jonathan	CO-FOUNDER	Mar 20 '26	Sale	199.95	1,500	299,931	21,032	Mar 20 09:05 PM
Sheena Jonathan	Director	Mar 20 '26	Proposed Sale	200.25	6,000	1,201,500		Mar 20 01:07 PM
Sheena Jonathan	Director	Mar 18 '26	Proposed Sale	198.16	12,441	2,465,309		Mar 18 11:19 AM
Chapman Rowan E	Director	Mar 13 '26	Sale	191.38	122	23,348	5,752	Mar 17 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 12 '26	Option Exercise	9.59	75,000	719,250	2,385,772	Mar 16 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 13 '26	Option Exercise	9.59	75,000	719,250	2,385,772	Mar 16 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 16 '26	Option Exercise	9.59	50,000	479,500	2,360,772	Mar 16 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 12 '26	Sale	190.59	75,000	14,294,119	2,310,772	Mar 16 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 13 '26	Sale	189.01	75,000	14,175,379	2,310,772	Mar 16 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 16 '26	Sale	196.28	50,000	9,813,883	2,310,772	Mar 16 09:05 PM
ROWAN EMMA CHAPMAN	Director	Mar 13 '26	Proposed Sale	191.38	122	23,348		Mar 13 04:19 PM
MATTHEW RABINOWITZ	Director	Mar 12 '26	Proposed Sale	196.61	200,000	39,322,000		Mar 12 04:29 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Mar 10 '26	Sale	204.13	785	160,244	63,354	Mar 11 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 10 '26	Sale	204.13	5,623	1,147,838	156,607	Mar 11 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Mar 10 '26	Sale	204.13	1,745	356,212	233,285	Mar 11 09:05 PM
Sheena Jonathan	CO-FOUNDER	Mar 10 '26	Sale	204.13	127	25,925	262,325	Mar 11 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Mar 10 '26	Sale	204.13	707	144,322	189,199	Mar 11 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Mar 10 '26	Sale	204.13	915	186,781	150,882	Mar 11 06:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Mar 06 '26	Option Exercise	19.68	5,598	110,169	241,683	Mar 10 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Mar 06 '26	Sale	196.08	8,398	1,646,696	233,285	Mar 10 09:05 PM
DANIEL RABINOWITZ	Officer	Mar 06 '26	Proposed Sale	197.14	16,798	3,311,558		Mar 06 04:29 PM
Sheena Jonathan	CO-FOUNDER	Mar 02 '26	Sale	200.23	3,070	614,710	262,194	Mar 03 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 02 '26	Sale	200.02	3,950	790,095	156,607	Mar 03 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Mar 02 '26	Option Exercise	9.59	5,125	49,149	153,023	Mar 03 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Mar 02 '26	Sale	199.85	3,000	599,545	150,023	Mar 03 09:05 PM
STEVEN L CHAPMAN	Officer	Mar 02 '26	Proposed Sale	200.02	3,950	790,095		Mar 02 04:12 PM
SOLOMON MOSHKEVICH	Officer	Mar 02 '26	Proposed Sale	199.85	3,000	599,545		Mar 02 04:11 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Feb 02 '26	Sale	231.44	3,000	694,309	139,486	Feb 04 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Feb 03 '26	Sale	230.77	1,639	378,229	137,847	Feb 04 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Feb 02 '26	Sale	230.72	85,299	19,680,040	127,881	Feb 04 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Feb 03 '26	Sale	230.77	4,725	1,090,379	123,156	Feb 04 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Feb 03 '26	Sale	227.83	6,939	1,580,926	52,120	Feb 04 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Feb 03 '26	Sale	231.02	3,594	830,279	178,081	Feb 04 09:05 PM
Sheena Jonathan	CO-FOUNDER	Feb 03 '26	Sale	230.77	435	100,384	263,161	Feb 04 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Feb 03 '26	Sale	230.77	1,334	307,845	223,813	Feb 04 09:05 PM
MICHAEL BROPHY	Officer	Feb 03 '26	Proposed Sale	231.10	5,671	1,310,568		Feb 03 04:32 PM
STEVEN L CHAPMAN	Officer	Feb 02 '26	Proposed Sale	230.72	85,299	19,679,799		Feb 02 04:58 PM
SOLOMON MOSHKEVICH	Officer	Feb 02 '26	Proposed Sale	231.44	3,000	694,309		Feb 02 04:12 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 28 '26	Sale	237.66	3,648	866,992	213,180	Jan 29 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 27 '26	Sale	240.53	2,322	558,514	216,828	Jan 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 28 '26	Sale	237.56	2,413	573,221	60,926	Jan 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 29 '26	Sale	230.40	1,867	430,156	59,059	Jan 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 27 '26	Sale	240.53	784	188,577	63,339	Jan 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Jan 27 '26	Sale	240.53	291	69,995	263,787	Jan 29 08:35 PM
Sheena Jonathan	CO-FOUNDER	Jan 28 '26	Sale	237.66	191	45,394	263,596	Jan 29 08:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 28 '26	Sale	237.66	1,000	237,662	225,147	Jan 29 08:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 27 '26	Sale	240.53	886	213,111	226,147	Jan 29 08:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

NTRA

Natera Inc

Upgrade your Finviz experience